Major biotech industry players had a terrible week, but it barely put a dent in their long-term performance. Why you shouldn't panic.
No health-care stocks in your portfolio? Here's why you're missing out on a great opportunity.
Boy, was it rough being a biotech investor on Friday: Two of today's three laggards hail from the high-flying industry.
We've collected the most popular companies among Fool.com readers, and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better Buy Tournament.
Big cap biotechs Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) have posted impressive gains in the past year that have all three trading at their highest valuation in years.
Sector Update: Healthcare Shares Flat Pre-Market; Novogen Soars 19% on Positive Outlook for Anti-Cancer DrugSee More Articles...